GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kairos Pharma Ltd (AMEX:KAPA) » Definitions » Net Issuance of Debt

KAPA (Kairos Pharma) Net Issuance of Debt : $-0.10 Mil (TTM As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Kairos Pharma Net Issuance of Debt?

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. Kairos Pharma's net issuance of debt for the three months ended in Mar. 2025 was $0.00 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Mar. 2025 was $-0.10 Mil.

Kairos Pharma Net Issuance of Debt Historical Data

The historical data trend for Kairos Pharma's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kairos Pharma Net Issuance of Debt Chart

Kairos Pharma Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Net Issuance of Debt
0.05 0.33 0.90 - -

Kairos Pharma Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.04 -0.14 -

Kairos Pharma Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kairos Pharma Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Kairos Pharma's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Kairos Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kairos Pharma Ltd (AMEX:KAPA) » Definitions » Net Issuance of Debt
Comparable Companies
ACXP ORGS KPRX APRE CYCN DWTX INTI SLXN BCDA NERV VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
2355 Westwood Boulevard, No. 139, Los Angeles, CA, USA, 90064
Website
https://www.kairospharma.com
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.